Alzheimer's Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Ability to provide a written informed consent form signed by the participant or a legal representative (e.g., immediate family member); 2.Age between 50 and 90 years (inclusive); 3.Clinically diagnosed with Alzheimer's disease; 4.Availability of relatively complete clinical data.
Exclusion criteria
Exclusion criteria: 1. Evidence of any non-Alzheimer’s disease (AD) condition that may affect cognitive function, including but not limited to: frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson’s disease, corticobasal syndrome, Creutzfeldt–Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration, Huntington’s disease, normal pressure hydrocephalus, epilepsy, delirium, or hypoxia; 2. History or current presence of clinically significant neurological disorders (e.g., traumatic brain injury, stroke, brain tumor, or previous brain surgery) that, in the opinion of the investigator, may impair cognitive function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive, Psychological, and Behavioral Assessments: CDR score;PET Imaging of Amyloid-ß (Aß) Deposition; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cerebrospinal Fluid (CSF) Biomarker Levels: Total tau (tTau) Phosphorylated tau at threonine 181 (pTau181) Amyloid-ß 40 (Aß40) Amyloid-ß 42 (Aß42);Cognitive, Psychological, and Behavioral Assessments: Activities of Daily Living (ADL) scale Mini-Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI);Regional Brain Volume on MRI; | — |
Countries
China
Contacts
The First Affiliated Hospital of Chongqing Medical University